Mikael Pittet

 

Professor Mikael Pittet completed his PhD thesis in Immunology at the Ludwig Institute for Cancer Research and graduated from the University of Lausanne in 2001. He pursued his research at Massachusetts General Hospital, Harvard Medical School, and Dana-Farber Cancer Institute, in Boston, United States, where he was named Samana Cay MGH Research Scholar in 2015, Director of the Center for Systems Biology Cancer Immunology Program in 2016, and full Professor at Harvard Medical School in 2019. He joined the Faculty of Medicine at UNIGE in 2020 where he is appointed full Professor in the Department of Pathology and Immunology, holding the ISREC Foundation Chair in Onco-
Immunology. He is also a full Member of Ludwig Cancer Research, member of the Department of Oncology of the University Hospitals of Geneva (HUG). Since 2022, he also directs the Translational Research Centre in Oncohaematology (CRTOH) at UNIGE. His research laboratory is located in Lausanne in the Agora Cancer Research Center, which assembles interdisciplinary research groups from various institutions to translate advances in cancer research to the clinic. Professor Pittet’s research focuses on uncovering how the immune system controls cancer and other diseases, and how it can be harnessed for therapy. His work has identified how cancers are regulated by various immune
cells, including cytotoxic T cells, regulatory T cells, macrophages, monocytes, neutrophils, and dendritic cells. These cells are considered as drug targets in cancer immunotherapy.
Professor Pittet is recognized as a Highly Cited Researcher based on his multiple papers that rank in the top 1% by citations during the last decade.